Subscribe Subscribe   Find us on Twitter Follow POL on Twitter  



Preemption and SSRI/suicide suits

Beck and Herrmann:

Initially, we'd invite anybody who doesn't think that plaintiffs in product liability litigation aren't asking state courts to ignore FDA decisions to read the statements of fact in either of these briefs. The causation claims plaintiffs advance in these cases have been rejected by the FDA time and time again.

Ditto for the concept of "overwarning." The proposition that too many warnings can have detrimental health effects by deterring the use of beneficial drugs isn't something made up by the Bush administration. The SSRI record detailed in these briefs indicates FDA concern about overwarning back in 1991. Moreover, as we've already noted, there's solid epidemiological evidence (only the largest increase in history in pediatric suicide rates coming hard on the heels of the addition of a pediatric suicide warning) indicating that the FDA's concern about overwarning is 100% legitimate - certainly where SSRIs are concerned.

Related Entries:



Rafael Mangual
Project Manager,
Legal Policy

Manhattan Institute


Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.